Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant

This article was originally published in The Pink Sheet Daily

Executive Summary

The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.


Related Content

Financings of the Fortnight Wants To Spin You Right 'Round, And Out
Financings Of The Fortnight: Do Larger Series A Rounds Mean Less Successful Exits?
Tigercat Pharma Results From A Regional Partnership For CMEA's Velocity
Financings Of The Fortnight: How To Read Conflicting Reports On VC Life-Sciences Activity
Versant Ventures Looks To Canada, Europe For New Deals
Start-Up Quarterly Statistics, Q4 2012
Financings Of The Fortnight: VCs May Be Up Against Trend Of Eliminating The “Middle-Man”
After Complex Sale, Amira Scientist And VC Team Up Again For Discovery Start-up
BMS Bets On Amira's IPF Drug In $325M Acquisition
Biotie To Combine With Synosia To Form A "Global Leader" In CNS Drug Development


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts